<DOC>
	<DOCNO>NCT01309152</DOCNO>
	<brief_summary>The investigator hypothesize cefazolin perfusion subcutaneous adipose tissue reduce morbidly obese patient . The primary objective exploratory pilot study therefore investigate target site ( subcutaneous adipose tissue ) penetration cefazolin morbidly obese patient non-obese patient . The investigator aim examine whether cefazolin plasma concentration predictive subcutaneous ( target ) cefazolin concentration . Possible factor influence distribution cefazolin ( tissue perfusion , body weight , distribution adipose tissue , ) identify .</brief_summary>
	<brief_title>Cefazolin Subcutaneous Microdialysis Morbidly Obese Patients</brief_title>
	<detailed_description />
	<mesh_term>Obesity , Morbid</mesh_term>
	<mesh_term>Cefazolin</mesh_term>
	<criteria>Body Mass Index &gt; 40 kg/m2 BMI 2025 undergo laparoscopic gastric banding , bypass surgery sleeve gastrectomy ( See population description surgery type nonobese group ) 2160 year old American Society Anaesthesiologists ( ASA ) physical status II III pregnancy breastfeed know allergy cefazolin/nadroparin know ejection fraction &lt; 35 % renal insufficiency</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>cefazolin</keyword>
	<keyword>microdialysis</keyword>
	<keyword>morbid obesity</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>